Manual práctico de Trombosis y Hemostasia de la SETH

I I I . H E M O ST A S I A E N L A P R Á C T I C A C L Í N I C A — 2 2 0 — 31. Park D, Southern W, Calvo M, Kushnir M, Solorzano C, Sinnet M, et al. Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. J Gen Intern Med 2016;31(2):182-7. 32. Li B, Lu D, Chen Y, Zhao M, Zuo L. Unfractionated heparin pro- motes osteoclast formation in vitro by inhibiting osteoprotegerin activity. Int J Mol Sci 2016;17(4):613. 33. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, WinkelmayerWC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015;66(4):677-88. 34. Fusaro M, D’Alessandro C, Noale M, et al. Low vitamin K1 intake in haemodialysis patients. Clin Nutr. 2017;36(2):601-7. 35. Han KH, O’NeillWC. Increased peripheral arterial calcification in patients receiving warfarin. J Am Heart Assoc 2016;5(1):1-8. 36. Lobos-Bejarano JM, Castellanos Rodríguez A, BarriosV, Escobar C, Polo-García J, del Castillo-Rodríguez JC, et al. Influence of renal function on anticoagulation control in patients with non-valvu- lar atrial fibrillation taking vitamin K antagonists. Int J Clin Pract 2017;71(9). DOI:10.1111/ijcp.12974. 37. Szummer K, Gasparini A, Eliasson S, Ärnlöv  J , Qureshi AR, Bárány P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with re- nal dysfunction. J Am Heart Assoc 2017;6(3). DOI:10.1161/ JAHA.116.004925. 38. Chan KE, Lazarus JM,Thadhani R, Hakim RM.Warfarin use asso- ciates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20(10):2223-33. 39. Schein JR,White CM,NelsonWW,Kluger J,Mearns ES,Coleman CI. Vitamin K antagonist use: Evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J 2016;13(14):14. 40. Albrecht D. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. Thromb Hae- most.2017;117(11):2026-33. 41. Qamar A, Bhatt DL. Stroke Prevention in Atrial Fibrilla- tion in Patients with Chronic Kidney Disease. Circulation 2016;133(15):1512-5. 42. Genovesi S, Carrero JJ. International Normalized Ratio Con- trol in Patients With Atrial Fibrillation and CKD. Am J Kidney Dis 2017;69:863. 43. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuha- ra S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation pa- tients with chronic kidney disease. Cochrane database Syst Rev 2017;11:CD011373. 44. Schwartz JB. Potential Effect of Substituting Estimated Glo- merular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants. J Am Geriatr Soc 2016;64(10):1996-2002. 45. Di Lullo L, Ronco C, Cozzolino M, Russo D, Russo  L , Di Iorio B, et al. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.Thromb Res 2017;155:38-47. 46. Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special consi- derations. Int J Nephrol Renovasc Dis 2017;10:135-43. 47. Ando G, Capranzano P. Non-vitamin K antagonist oral anticoa- gulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. Int J Cardiol 2017;231:162-9. 48. Diener HC,Aisenberg J,Ansell J,Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrilla- tion: Part 2. Eur Heart J 2017;38(12):860-8. 49. Sciascia S, Radin M, Schreiber K, Fenoglio R, Baldovino S, Rocca- tello D. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med 2017;12(8):1101-8. 50. Goldhaber SZ, Schulman S, Eriksson H, Feuring M, Fraessdorf M, Kreuzer J, et al. Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Pa- tients: Pooled Analysis of RE-COVER and RE-COVER II.Thromb Haemost 2017;117(11):2045-52. 51. Knauf F, Chaknos CM, Berns JS, Perazella MA. Dabigatran and kidney disease: A bad combination. Clin J Am Soc Nephrol 2013;8(9):1591-7. 52. RaccahBH,PerlmanA,DanenbergHD,PollakA,MuszkatM,MatokI. Major Bleeding and Hemorrhagic Stroke with Direct Oral An- ticoagulants in Patients with Renal Failure Systematic Review and Meta-Analysis of Randomized Trials. Chest 2016;149(6): 1516-24. 53. Wang X, Tirucherai G, Marbury TC, Chang M, Zhang D, Song Y, et al. Pharmacokinetics, pharmacodynamics, and safety of apixa- ban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56(5):628-36. 54. Pelliccia F, Rosanio S, Marazzi G, Poggi S, Tanzilli A, Greco C, et al. Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. Int J Cardiol 2016;225:77-81. 55. Büller HR, Décousus H, Grosso M, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406-15. 56. Arepally GM. Heparin-induced thrombocytopenia. Blood 2017;129(21):2864-72. 57. Job H, Ingrid J,Tivadar F, Lukas P.Treatment of patients with a his- tory of heparin-induced thrombocytopenia and anti-lepirudin anti- bodies with argatroban. J ThrombThrombolysis 2005;19(1):65-9. 58. Wheeler DS, Giugliano RP, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost 2016;14(3):461-7.